<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00080665</url>
  </required_header>
  <id_info>
    <org_study_id>J0214 CDR0000354504</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0214</secondary_id>
    <secondary_id>SKCCC-J0214</secondary_id>
    <nct_id>NCT00080665</nct_id>
  </id_info>
  <brief_title>Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I Study Of Weekly Taxotere (Docetaxel) And Gleevec (STI571, Imatinib Mesylate, CGP 57148B) In Locally Advanced Or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of&#xD;
      tumor cells by blocking the enzymes necessary for their growth. Giving docetaxel with&#xD;
      imatinib mesylate may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel when&#xD;
      given together with imatinib mesylate in treating patients with locally advanced or&#xD;
      metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety profile, maximum tolerated dose, and recommended phase II dose of&#xD;
           docetaxel when administered with imatinib mesylate in patients with locally advanced or&#xD;
           metastatic breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine the potential effects of this regimen on CYP3A4 activity and docetaxel&#xD;
           metabolism in these patients.&#xD;
&#xD;
        -  Correlate docetaxel and imatinib mesylate exposure (utilizing total and unbound&#xD;
           docetaxel and imatinib mesylate plasma concentrations) with drug response (e.g.,&#xD;
           pharmacodynamic effects, drug toxicity, and response) in these patients.&#xD;
&#xD;
        -  Determine response rate, duration of response, and time to treatment failure in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Correlate proteomic profile changes in serum with tumor burden and response in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Correlate pharmacokinetic parameters, tissue expression of specific receptor tyrosine&#xD;
           kinases (e.g., c-Kit, platelet-derived growth factor receptor [PDGFR], and&#xD;
           phosphorylated PDGFR) in paraffin blocks, and pharmacodynamic assays with antitumor&#xD;
           activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of docetaxel.&#xD;
&#xD;
      Patients receive docetaxel IV over 1 hour on days 1, 8, and 15 and oral imatinib mesylate&#xD;
      (STI571) on days 8-28 of course 1 and days 1-28 of all subsequent courses. Courses repeat&#xD;
      every 28 days in the absence of disease progression or unacceptable toxicity*. Patients with&#xD;
      stable or responding disease after at least 2 courses of therapy may discontinue docetaxel&#xD;
      and continue therapy with single-agent STI571 until disease progression.&#xD;
&#xD;
      NOTE: *Patients experiencing excessive docetaxel-related toxicity who have completed at least&#xD;
      2 full courses may continue on single-agent STI571 in the absence of disease progression or&#xD;
      excessive STI571-related toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of docetaxel until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity. An additional cohort of 6-12 patients&#xD;
      receives treatment at the MTD.&#xD;
&#xD;
      Patients are followed at 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately of 18-30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2.1.1 To determine the safety profile, maximum tolerated dose, and recommended dose for subsequent phase II studies of a combination regimen of daily STI571 with weekly docetaxel on days 1, 8, and 15 in a 28-day cycle.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Imatinib mesylate and docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imatinib mesylate (400-600 mg, oral, once daily) and docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle</description>
    <arm_group_label>Imatinib mesylate and docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>Imatinib mesylate (400-600 mg, oral, once daily) each 28 day cycle</description>
    <arm_group_label>Imatinib mesylate and docetaxel</arm_group_label>
    <other_name>Gleevec, STI571</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the breast&#xD;
&#xD;
               -  Stage IIIB, IIIC, or IV disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Stable brain metastases allowed provided prior surgery or radiotherapy was completed&#xD;
             more than 90 days ago&#xD;
&#xD;
          -  No documented or suspected leptomeningeal disease&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ upper limit of normal (ULN)&#xD;
&#xD;
          -  Meets 1 of the following criteria for AST or ALT AND alkaline phosphatase:&#xD;
&#xD;
               -  AST or ALT ≤ ULN AND alkaline phosphatase ≤ 5 times ULN&#xD;
&#xD;
               -  AST or ALT ≤ 2.5 times ULN AND alkaline phosphatase ≤ ULN&#xD;
&#xD;
               -  AST or ALT ≤ 1.5 times ULN AND alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  No known acute or chronic liver disease (e.g., chronic active hepatitis or cirrhosis)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 3 months&#xD;
             after study participation&#xD;
&#xD;
          -  No other primary malignancy except those malignancies that are clinically&#xD;
             insignificant AND do not require active intervention&#xD;
&#xD;
          -  No other concurrent severe and/or life-threatening medical disease&#xD;
&#xD;
          -  No significant history of noncompliance to medical regimens or inability to grant&#xD;
             reliable informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 14 days since prior systemic trastuzumab (Herceptin®)&#xD;
&#xD;
          -  No concurrent trastuzumab&#xD;
&#xD;
          -  No concurrent biologic therapy for the primary malignancy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior taxane therapy, including docetaxel, in the adjuvant or metastatic setting&#xD;
             allowed&#xD;
&#xD;
          -  At least 21 days since prior systemic chemotherapy (14 days for weekly or oral&#xD;
             chemotherapy and 42 days for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 14 days since prior systemic hormonal therapy&#xD;
&#xD;
          -  No concurrent antiestrogen therapy&#xD;
&#xD;
          -  No concurrent routine systemic corticosteroid therapy except as premedication for&#xD;
             chemotherapy&#xD;
&#xD;
          -  Concurrent megestrol allowed only as an appetite stimulant&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 14 days since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to only site of measurable/evaluable disease unless there is new&#xD;
             evidence of post-radiotherapy disease progression&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 2 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  At least 14 days since prior daily or weekly systemic investigational treatment&#xD;
&#xD;
          -  No concurrent warfarin for full anticoagulation&#xD;
&#xD;
               -  Concurrent low-dose warfarin (e.g., 1 mg/day) allowed for prophylaxis of central&#xD;
                  venous access&#xD;
&#xD;
          -  No concurrent treatment with any of the following:&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Barbiturates&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
          -  No other concurrent therapies for the primary malignancy&#xD;
&#xD;
          -  No other concurrent investigational drugs or systemic therapy&#xD;
&#xD;
          -  No concurrent bisphosphonates unless started before study therapy&#xD;
&#xD;
          -  No concurrent grapefruit juice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio C. Wolff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Fetting JH, Emens LA, Stearns V, Davidson NE, Baker SD, Wolff AC. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat. 2011 May;127(1):153-62. doi: 10.1007/s10549-011-1413-6. Epub 2011 Feb 25.</citation>
    <PMID>21350820</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 7, 2004</study_first_submitted>
  <study_first_submitted_qc>April 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2004</study_first_posted>
  <last_update_submitted>April 22, 2018</last_update_submitted>
  <last_update_submitted_qc>April 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>male breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

